These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors. Chen KY; Krischuns T; Ortega Varga L; Harigua-Souiai E; Paisant S; Zettor A; Chiaravalli J; Courtney D; O'Brien A; Baker SC; Isel C; Agou F; Jacob Y; Blondel A; Naffakh N bioRxiv; 2021 Dec; ():. PubMed ID: 34981051 [TBL] [Abstract][Full Text] [Related]
3. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor. O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599 [TBL] [Abstract][Full Text] [Related]
4. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease. Milligan JC; Zeisner TU; Papageorgiou G; Joshi D; Soudy C; Ulferts R; Wu M; Lim CT; Tan KW; Weissmann F; Canal B; Fujisawa R; Deegan T; Nagaraj H; Bineva-Todd G; Basier C; Curran JF; Howell M; Beale R; Labib K; O'Reilly N; Diffley JFX Biochem J; 2021 Jul; 478(13):2499-2515. PubMed ID: 34198327 [TBL] [Abstract][Full Text] [Related]
6. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2. Abdizadeh R; Hadizadeh F; Abdizadeh T Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728 [TBL] [Abstract][Full Text] [Related]
7. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening. Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802 [TBL] [Abstract][Full Text] [Related]
8. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
9. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening. Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706 [No Abstract] [Full Text] [Related]
11. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro). Rothan HA; Teoh TC Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543 [TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2. Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies. Tatar G; Salmanli M; Dogru Y; Tuzuner T J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547 [TBL] [Abstract][Full Text] [Related]
14. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539 [TBL] [Abstract][Full Text] [Related]
15. Identification of Novel Drug Candidates for the Inhibition of Catalytic Cleavage Activity of Coronavirus 3CL-like Protease Enzyme. Gurung AB; Al-Anazi KM; Ali MA; Lee J; Farah MA Curr Pharm Biotechnol; 2022; 23(7):959-969. PubMed ID: 34097590 [TBL] [Abstract][Full Text] [Related]
16. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses. Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603 [TBL] [Abstract][Full Text] [Related]
17. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. Kumar V; Roy K SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892 [TBL] [Abstract][Full Text] [Related]
18. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Novak J; Potemkin VA Mol Divers; 2022 Oct; 26(5):2631-2645. PubMed ID: 35001230 [TBL] [Abstract][Full Text] [Related]
20. Interaction of HDAC2 with SARS-CoV-2 NSP5 and IRF3 Is Not Required for NSP5-Mediated Inhibition of Type I Interferon Signaling Pathway. Naik NG; Lee SC; Veronese BHS; Ma Z; Toth Z Microbiol Spectr; 2022 Oct; 10(5):e0232222. PubMed ID: 36173315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]